Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 196

Sort by

Sort Order Select

Journal Articles

CLL-IPI: valid in the era of oral inhibitors?

Nadine Kutsch

Blood (2021) 138 (2): 106–107.

https://doi.org/10.1182/blood.2021011937

Published: 2021

Journal Articles

Acalabrutinib in treatment-naive chronic lymphocytic leukemia

John C. Byrd, Jennifer A. Woyach, Richard R. Furman, Peter Martin, Susan O’Brien, Jennifer R. Brown, Deborah M. Stephens, Jacqueline C. Barrientos, Stephen Devereux, Peter Hillmen, John M. Pagel, Ahmed Hamdy, Raquel Izumi, Priti Patel, Min Hui Wang, Nitin Jain, William G. Wierda

Blood (2021) 137 (24): 3327–3338.

https://doi.org/10.1182/blood.2020009617

Published: 2021

Includes: Supplemental data

Journal Articles

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Yair Herishanu, Irit Avivi, Anat Aharon, Gabi Shefer, Shai Levi, Yotam Bronstein, Miguel Morales, Tomer Ziv, Yamit Shorer Arbel, Lydia Scarfò, Erel Joffe, Chava Perry, Paolo Ghia

Blood (2021) 137 (23): 3165–3173.

https://doi.org/10.1182/blood.2021011568

Published: 2021

Includes: Supplemental data

Journal Articles

The miR-185/PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemic stem cells in CML

Blood (2020) 136 (5): 596–609.

https://doi.org/10.1182/blood.2019003636

Published: 2020

Includes: Supplemental data

Journal Articles

Occupy BTK: the key to controlling CLL

Philip A. Thompson

Blood (2020) 136 (1): 4–6.

https://doi.org/10.1182/blood.2020005877

Published: 2020

Journal Articles

A complementary new drug for PNH

Robert A. Brodsky

Blood (2020) 135 (12): 884–885.

https://doi.org/10.1182/blood.2020004959

Published: 2020

Journal Articles

The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria

Blood (2020) 135 (12): 912–920.

https://doi.org/10.1182/blood.2019003399

Published: 2020

Includes: Supplemental data

Journal Articles

Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials

Jennifer A. Woyach

Blood (2019) 134 (21): 1796–1801.

https://doi.org/10.1182/blood.2019001321

Published: 2019

Journal Articles

Dactinomycin in Acute Myeloid Leukemia with NPM1 Mutations

Guillaume Beziat, Suzanne Tavitian, MD, Sarah Bertoli, MD PhD, Francoise Huguet, MD, Laetitia Largeaud, Francois Vergez, DVM, PhD, Jean-Baptiste Rieu, PharmD, Pierre Bories, MD, Eric Delabesse, MD PhD, Christian Recher, MD PhD

Blood (2019) 134 (Supplement_1): 3900.

https://doi.org/10.1182/blood-2019-125782

Published: 2019

Journal Articles

Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation

Reem Karmali, MD, Jeremy S. Abramson, MD MMSc, Deborah M. Stephens, DO, Jeffrey A. Barnes, MD PhD, Jason Kaplan, MD, Jane N. Winter, MD, Shuo Ma, MD PhD, Juehua Gao, MD PhD, Adam M. Petrich, MD, Ephraim Hochberg, MD, Ronald W. Takvorian, MD, Frank Kuhr, PhD, Valerie Nelson, MD MBA, Leo I. Gordon, MD, Barbara Pro, MD

Blood (2019) 134 (Supplement_1): 3990.

https://doi.org/10.1182/blood-2019-126920

Published: 2019

Journal Articles

Platelet Dysfunction Detected Using Rotational Thromboelastometry (ROTEM) in Severely Thrombocytopenic Patients with a Bleeding Phenotype

Philip Young-Ill Choi, BSc, MBBS, PhD, Sarah Hicks, Elizabeth E. Gardiner, PhD, Philip Crispin, MBBS, FRACP, FRCPA, James Slade, BN, GCCaN, MNNP, James D'Rozario, MBBS, FRACP, FRCPA, Christopher Parish, PhD, Lucy Coupland, PhDBSc,RN

Blood (2019) 134 (Supplement_1): 2357.

https://doi.org/10.1182/blood-2019-132232

Published: 2019

Journal Articles

High Surface Expression of CD49d (VLA-4) and CD79b Correlates with Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia (CLL)

Elena Bibikova, Brian Law, Tracy Clevenger, PhD, Jean Cheung, MS, Gary De Jesus, Michael Gulrajani, Kyoko Yamaguchi, Phuong Do, Kathleen Burke, PhD, Graham Brock, PhD, Veerendra Munugalavadla, PhD, Melanie M. Frigault, PhD, John C. Byrd, MD, Richard R. Furman, MD, Jennifer R. Brown, MD PhD, Todd Covey

Blood (2019) 134 (Supplement_1): 2571.

https://doi.org/10.1182/blood-2019-128872

Published: 2019

Journal Articles

Individualized Mitochondrial Functional Approach to Combination of BCL-2 and MCL-1 Antagonism in Acute Myeloid Leukemia

Shruti Bhatt, PhD, Marissa Pioso, Elyse Ann Olesinski, Binyam Yilma, Leutz Buon, Sophia Adamia, PhD, Holly Zhu, Jeremy Ryan, Youzhen Wang, Morris Erick, Ensar Halilovic, David M. Weinstock, MD, Jacqueline S Garcia, MD, Anthony Letai

Blood (2019) 134 (Supplement_1): 2551.

https://doi.org/10.1182/blood-2019-131101

Published: 2019

Journal Articles

High Frequency Mutations of MYD88 and KMT2D in Chinese Chronic Lymphocytic Leukemia

Shuhua Yi, MD, Yuting Yan, Meiling Jin, Dr., Wenjie Xiong, Zengjun Li, Ying Yu, Rui Cui, MD, Zhen Yu, MD, Yani Lin, Wang Jun, Tingyu Wang, Wei Liu, Kun Ru, MD, Lili Wang, MD PhD, Lugui Qiu, MD PhD

Blood (2019) 134 (Supplement_1): 2761.

https://doi.org/10.1182/blood-2019-123194

Published: 2019

Journal Articles

Response to the Shingrix Varicella Zoster Virus (VZV) Vaccine in Patients with Chronic Lymphocytic Leukemia (CLL) That Are Treatment Naive or Treated with a Bruton's Tyrosine Kinase Inhibitor (BTK-I)

Christopher Pleyer, MD, Jeffrey Cohen, MD, Susan Soto, Mir Ali, PhD, Inhye E Ahn, MD, Pia Nierman, BSN, MA, RN, Janet Valdez, Jennifer Lotter, PA-C, Jeanine Superata, RN, Xin Tian, Adrian Wiestner, MD PhD, Clare Sun, MD

Blood (2019) 134 (Supplement_1): 3053.

https://doi.org/10.1182/blood-2019-121675

Published: 2019

Journal Articles

Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-Cell Lymphoma (PTCL) in Adults Age 60 and Above

Christopher A. Yasenchak, MD, Rodolfo Bordoni, MD, Victor Yazbeck, MD, Dipti Patel-Donnelly, MD, Timothy Larson, MD, Trevor Newhook, MS, Linda Ho, Matthew Mei, MD

Blood (2019) 134 (Supplement_1): 2852.

https://doi.org/10.1182/blood-2019-122968

Published: 2019

Journal Articles

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial

Blood (2019) 134 (Supplement_1): 499.

https://doi.org/10.1182/blood-2019-125394

Published: 2019

Journal Articles

The Use of Venetoclax for Acute Myeloid Leukemia in a Real-Life Setting: A Multicenter National Experience

Blood (2019) 134 (Supplement_1): 5098.

https://doi.org/10.1182/blood-2019-128583

Published: 2019

Journal Articles

Integrative Immunogenomic Characterization of Diffuse Large B-Cell Lymphoma (DLBCL) Identifies Four Molecular Subtypes with Distinct Immune Landscapes

Michael Leukam, MDMS, James Godfrey, MD, Sravya Tumuluru, Girish Venkataraman, MD MBBS, Sonali M. Smith, MD, Riyue Bao, PhD, Justin Kline, MD

Blood (2019) 134 (Supplement_1): 924.

https://doi.org/10.1182/blood-2019-131562

Published: 2019

Journal Articles

Combination of ATRA and High-Dose Dexamethasone As First-Line Treatment in Adult Immune Thrombocytopenia:a Randomized, Phase 2, Open-Label Trial

Qiu-Sha Huang, Yi Liu, Jing-Bo Wang, Jun Peng, Ming Hou, Hui Liu, Jing-Wen Wang, Lan-Ping Xu, Kaiyan Liu, Xiao-Jun Huang, MD, Xiao-Hui Zhang

Blood (2019) 134 (Supplement_1): 899.

https://doi.org/10.1182/blood-2019-125242

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

CLL-IPI: valid in the era of oral inhibitors?

Acalabrutinib in treatment-naive chronic lymphocytic leukemia

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

The miR-185/PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemic stem cells in CML

Occupy BTK: the key to controlling CLL

A complementary new drug for PNH

The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria

Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials

Dactinomycin in Acute Myeloid Leukemia with NPM1 Mutations

Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation

Platelet Dysfunction Detected Using Rotational Thromboelastometry (ROTEM) in Severely Thrombocytopenic Patients with a Bleeding Phenotype

High Surface Expression of CD49d (VLA-4) and CD79b Correlates with Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia (CLL)

Individualized Mitochondrial Functional Approach to Combination of BCL-2 and MCL-1 Antagonism in Acute Myeloid Leukemia

High Frequency Mutations of MYD88 and KMT2D in Chinese Chronic Lymphocytic Leukemia

Response to the Shingrix Varicella Zoster Virus (VZV) Vaccine in Patients with Chronic Lymphocytic Leukemia (CLL) That Are Treatment Naive or Treated with a Bruton's Tyrosine Kinase Inhibitor (BTK-I)

Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-Cell Lymphoma (PTCL) in Adults Age 60 and Above

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial

The Use of Venetoclax for Acute Myeloid Leukemia in a Real-Life Setting: A Multicenter National Experience

Integrative Immunogenomic Characterization of Diffuse Large B-Cell Lymphoma (DLBCL) Identifies Four Molecular Subtypes with Distinct Immune Landscapes

Combination of ATRA and High-Dose Dexamethasone As First-Line Treatment in Adult Immune Thrombocytopenia:a Randomized, Phase 2, Open-Label Trial

Email alerts

ASH Publications

American Society of Hematology